Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 27;28(11):e1017–e1030. doi: 10.1093/oncolo/oyad157

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Survival by Kaplan-Meier estimates. (A) Overall survival of population-based cohort (n = 516); 95% CI indicated for 12, 24, and 36 months. (B) Overall survival of population-based cohort stratified by different subtypes and unclassified lymphoma. (C) Survival of population-based cohort with at least 1 month of survival (n = 296) with respect to therapy initiation and (D) those surviving at least 1 month that initiated any chemotherapy (n = 174), with respect to completion of chemo(immuno-)therapy cycles. (E) Survival of DLBCL with at least 1 month of survival (n = 74) with respect to therapy initiation and (F) DLBCL patients surviving at least 1 month that received any chemo(immuno-)therapy (n = 55) with respect to therapy completion concording with NCCN guidelines harmonized for Sub-Saharan Africa. No, Number; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; F-up, follow-up.